A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis

Critical Care

Volumn 17, Issue 6, 2013, Pages

  Gando, Satoshi ^a   Saitoh, Daizoh ^b   Ishikura, Hiroyasu ^c   Ueyama, Masashi ^d   Otomo, Yasuhiro ^e   Oda, Shigeto ^f   Kushimoto, Shigeki ^g   Tanjoh, Katsuhisa ^h   Mayumi, Toshihiko ⁱ   Ikeda, Toshiaki ^j   Iba, Toshiaki ^k   Eguchi, Yutaka ^l   Okamoto, Kohji ^m   Ogura, Hiroshi ⁿ   Koseki, Kazuhide ^o   Sakamoto, Yuichiro ^p   Takayama, Yasuhiro ^o   Shirai, Kunihiro ^q   Takasu, Osamu ^r   Inoue, Yoshiaki ^s   Mashiko, Kunihiro ^t   Tsubota, Takaya ^u   Endo, Shigeatsu ^v   more..

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^c FUKUOKA UNIVERSITY   (Japan)

^d CHUKYO HOSPITAL   (Japan)

^e TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^f CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^j TOKYO MEDICAL UNIVERSITY HACHIOJI MEDICAL CENTER   (Japan)

^k JUNTENDO UNIVERSITY   (Japan)

^l SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^m UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

ⁿ OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^o Kawaguchi Municipal Medical Center   (Japan)

^p SAGA UNIVERSITY   (Japan)

^q GIFU UNIVERSITY   (Japan)

^r KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^s JUNTENDO UNIVERSITY URAYASU HOSPITAL   (Japan)

^t NIPPON MEDICAL SCHOOL   (Japan)

^u TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

^v IWATE MEDICAL UNIVERSITY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; GABEXATE MESILATE; NAFAMSTAT MESILATE; GABEXATE;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; COMPARATIVE STUDY; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFECT; DRUG EFFICACY; FEMALE; FIBRINOLYSIS; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBOCYTE COUNT; TREATMENT DURATION; VERY ELDERLY; BLOOD CLOTTING; CLINICAL TRIAL; COMPLICATION; DISSEMINATED INTRAVASCULAR COAGULATION; DRUG ADMINISTRATION; DRUG EFFECTS; TREATMENT OUTCOME;

AGED; ANTITHROMBINS; BLOOD COAGULATION; DISSEMINATED INTRAVASCULAR COAGULATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FIBRINOLYSIS; GABEXATE; HUMANS; MALE; PLATELET COUNT; PROSPECTIVE STUDIES; SEPSIS; TREATMENT OUTCOME;

EID: 84890278513     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc13163     Document Type: Article

References (36)

1. Wiedermann CJ. Clinical review: molecular mechanisms underlying the role of antithrombin in sepsis. Crit Care 2006, 10:209. 10.1186/cc4822, 1550851, 16542481.
2. Opal SM. Therapeutic rationale for antithrombin III in sepsis. Crit Care Med 2000, 28:S34-S37. 10.1097/00003246-200009001-00008, 11007195.
3. Fourrier F, Jourdain M, Tournoys A. Clinical trial results with antithrombin III in sepsis. Crit Care Med 2000, 28:S38-S43. 10.1097/00003246-200009001-00009, 11007196.
4. Fourrier F, Chopin C, Huart JJ, Runge I, Caron C, Goudemand J. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intra vascular coagulation. Chest 1993, 104:882-888.
5. Eisele B, Lamy M, Thijs LG, Keinecke HO, Schuster HP, Matthias FR, Fourrier F, Heinrichs H, Delvos U. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med 1998, 24:663-672. 10.1007/s001340050642, 9722035.
6. Baudo F, Caimi TM, De Cataldo F, Ravizza A, Artati S, Casella G, Carugo D, Palareti G, Legnami C, Ridolfi L, Rossi R, D'Angelo A, Crippa L, Giudici D, Gallioli G, Wolfer A, Caloli G. Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med 1998, 24:336-342. 10.1007/s001340050576, 9609411.
7. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Pénzes I, Kübler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Opal SM, For the KyberSept Trial Study Group High-dose antithrombin III in severe sepsis. A randomized controlled trial. JAMA 2001, 286:1869-1878. 10.1001/jama.286.15.1869, 11597289, For the KyberSept Trial Study Group.
8. DePalo V, Kessler C, Opal SM. Success or failure in phase III sepsis trials: comparisons between the Drotorecogin alfa (activated) and antithrombin III clinical trials. Advance in Sepsis 2001, 1:114-124.
9. Hoffmann JN, Wiedermann CJ, Juers H, Ostermann H, Kienast J, Briegel J, Strauss R, Warren BL, Opal SM, For the KyberSepst investigators Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thromb Haemost 2006, 95:850-856. For the KyberSepst investigators.
10. Wiedermann CJ, Hoffmann JN, Juers M, Ostermann H, Kienast J, Briegel J, Strauss R, Keinecke HO, Warren BL, Opal SM, For the KyberSept investigators High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit Care Med 2006, 34:285-292. 10.1097/01.CCM.0000194731.08896.99, 16424704, For the KyberSept investigators.
11. Eid A, Wiedermann CJ, Kinasewitz GT. Early administration of high-dose antithrombin in severe sepsis: single center results from the KyberSepst Trial. Anesth Analg 2008, 107:1633-1638. 10.1213/ane.0b013e318184621d, 18931224.
12. Afshari A, Wettersiev J, Brok J, Møller A. Antithrombin III in critically ill patients: systematic review with meta-analysis and trial sequential analysis. BMJ 2007, 335:1248-1251. 10.1136/bmj.39398.682500.25, 2137061, 18037615.
13. Kienast J, Juers M, Wiedermann CJ, Hoffmann JN, Ostermann H, Strauss R, Keiecke HO, Warren BL, Opal SM, For the KyberSepst investigators Treatment effects of high-dose antithrombin III without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 2006, 4:90-97. For the KyberSepst investigators.
14. Wiedermann CJ, Kaneider NC. A systematic review of antithrombin concentrate use in patients with disseminated intravascular coagulation of severe sepsis. Blood Coagul Fibrinolysis 2006, 17:521-526. 10.1097/01.mbc.0000245302.18010.40, 16988545.
15. Gando S, Kameue T, Nanzaki S, Nakanishi Y. Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome. Thromb Haemost 1996, 75:224-228.
16. Rangel-Flausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995, 273:117-123. 10.1001/jama.1995.03520260039030, 7799491.
17. Gando S, Nanzaki S, Sasaki S, Aoi K, Kemmotsu O. Activation of the extrinsic coagulation pathway in patients with severe sepsis and septic shock. Crit Care Med 1998, 26:2005-2009. 10.1097/00003246-199812000-00030, 9875912.
18. Fourrier F. Severe sepsis, coagulation, and fibrinolysis: dead end or one way?. Crit Care Med 2012, 40:2704-2708. 10.1097/CCM.0b013e318258ff30, 22732284.
19. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL, , et al. International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American College of Emergency Physicians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases; European Society of Intensive Care Medicine Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008, 36:296-327. 10.1097/01.CCM.0000298158.12101.41, 18158437, International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American College of Emergency Physicians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases; European Society of Intensive Care Medicine.
20. Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference committee: American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Definition for sepsis and organ failure and guidelines for the use innovative therapies in sepsis. Crit Care Med 1992, 20:864-874. 10.1097/00003246-199206000-00025, 1597042, Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference committee: American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference.
21. Knaus WA, Draper EA, Wanger DP, Zimmerman JE. APACHE II: a severity classification system. Crit Care Med 1985, 13:818-829. 10.1097/00003246-198510000-00009, 3928249.
22. Ferreira FL, Bota DP, Bross A, Mélot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 2001, 286:1754-1758. 10.1001/jama.286.14.1754, 11594901.
23. Gando S, Iba T, Eguchi Y, Otomo Y, Okamoto K, Koseki K, Mayumi T, Murata A, Ikeda T, Ishikura H, Ueyama M, Ogura H, Kushimoto S, Saitoh D, Endo S, Shimazaki S, Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) study group A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med 2006, 34:625-631. Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) study group.
24. Gando S, Saitoh D, Ogura H, Mayumi T, Koseki K, Ikeda T, Ishikura H, Iba T, Ueyama M, Eguchi Y, Otomo Y, Okamoto K, Kushimoto S, Endo S, Shimazaki S, Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) study group Natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria for critically ill patients: results of a multicenter, prospective survey. Crit Care Med 2008, 36:145-150. 10.1097/01.CCM.0000295317.97245.2D, 18090367, Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) study group.
25. Taylor FBJ, Toh CH, Hoots WK, Wada H, Levi M. Toward definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001, 86:1327-1330.
26. Sawamura A, Gando S, Hayakawa M, Hoshino H, Kubota N, Sugano M. Effects of antithrombin III in patients with disseminated intravascular coagulation diagnosed by newly developed diagnostic criteria for critical illness. Clin Appl Thromb Hemost 2009, 15:561-566. 10.1177/1076029608323497, 18840625.
27. Iba T, Saito S, Wada H, Asakura H. Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: a prospective multicenter survey. Thromb Res 2012, 130:e129-e133. 10.1016/j.thromres.2012.03.021, 22542365.
28. Gonano C, Sitzwohl C, Meitner E, Weinstabl C, Kettner SC. Four-day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Crit Care 2006, 10:R160. 10.1186/cc5098, 1794466, 17107615.
29. Hoffmann KH, Mühlbayer D, Jochum M, Inthorn D. Effects of long-term and high-dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Crit Care Med 2004, 32:1851-1859. 10.1097/01.CCM.0000139691.54108.1F, 15343012.
30. Saitoh D, Okamoto K, Mayumi T, Koseki K, Ogura Y, Iba T, Eguchi Y, Otomo Y, Ikeda H, Ishikura H, Ueyama M, Kushimoto S, Endo S, Shimazaki S, Gando S. The post-hoc analysis of the second multicenter prospective study of the JAAM DIC study group: analysis of the effects of treatments methods for DIC. JJAAM 2007, 18:262-272.
31. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. Br J Haemost 2009, 145:24-33.
32. Di Nisio M, Baudo F, Cosmi B, D'Angelo A, De Gasperi A, Malato A, Schiavoni M, Squizzato A, On behalf of the Italian Society for Thrombosis and Haemostasis Diagnosis and treatment of disseminated intravascular coagulation: guidelines of the Italian society for haemostasis and thrombosis (SISET). Thromb Res 2012, 129:e177-e184. 10.1016/j.thromres.2011.08.028, 21930293, On behalf of the Italian Society for Thrombosis and Haemostasis.
33. Wada H, Asakura H, Okamoto K, Iba T, Uchiyama T, Kawasugi K, Koga S, Mayumi T, Koike K, Gando S, Kushimoto S, Seki Y, Madoiwa S, Maruyama I, Yoshioka A, Japanese Society of Thrombosis and Hemostasis DIC subcommittee Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb Res 2010, 125:6-11. 10.1016/j.thromres.2009.08.017, 19782389, Japanese Society of Thrombosis and Hemostasis DIC subcommittee.
34. Nishiyama T, Matsukawa T, Hanaoka K. Is protease inhibitor a choice for the treatment of pre- or mild disseminated intravascular coagulation?. Crit Care Med 2000, 28:1419-1422. 10.1097/00003246-200005000-00027, 10834689.
35. Nishiyama T, Kohno Y, Koishi K. Effects of antithrombin and gabexate mesilate on disseminated intravascular coagulation: a preliminary study. Am J Emerg Med 2012, 30:1219-1223. 10.1016/j.ajem.2011.06.003, 22204993.
36. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomized control trials. BMJ 1999, 319:670-674. 10.1136/bmj.319.7211.670, 28218, 10480822.